189 related articles for article (PubMed ID: 9701362)
1. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.
Zou Y; Zong G; Ling YH; Hao MM; Lozano G; Hong WK; Perez-Soler R
J Natl Cancer Inst; 1998 Aug; 90(15):1130-7. PubMed ID: 9701362
[TBL] [Abstract][Full Text] [Related]
2. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer.
Zou Y; Zong G; Ling YH; Perez-Soler R
Cancer Gene Ther; 2000 May; 7(5):683-96. PubMed ID: 10830716
[TBL] [Abstract][Full Text] [Related]
3. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
Zhang WW; Fang X; Mazur W; French BA; Georges RN; Roth JA
Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
Fujiwara T; Cai DW; Georges RN; Mukhopadhyay T; Grimm EA; Roth JA
J Natl Cancer Inst; 1994 Oct; 86(19):1458-62. PubMed ID: 8089864
[TBL] [Abstract][Full Text] [Related]
5. [Effects of adenovirus-mediated p16 and p53 genes transfer on apoptosis and cell cycle of lung carcinoma cells].
Bai X; Che F; Li J; Ma Y; Zhou Y; Zhai J; Meng L
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):354-8. PubMed ID: 11866935
[TBL] [Abstract][Full Text] [Related]
6. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Ling YH; Zou Y; Perez-Soler R
Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
[TBL] [Abstract][Full Text] [Related]
7. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy.
Seki M; Iwakawa J; Cheng H; Cheng PW
Hum Gene Ther; 2002 Apr; 13(6):761-73. PubMed ID: 11936974
[TBL] [Abstract][Full Text] [Related]
8. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy with tumor suppressor gene p53 and(or) p16 on the nude mice models of NSCLC in vivo].
Wu W; Zhang X; Qi X
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jul; 23(7):403-5. PubMed ID: 11778504
[TBL] [Abstract][Full Text] [Related]
10. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC.
Kim CK; Choi EJ; Choi SH; Park JS; Haider KH; Ahn WS
Gynecol Oncol; 2003 Aug; 90(2):265-72. PubMed ID: 12893186
[TBL] [Abstract][Full Text] [Related]
11. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
Riva CM
Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
[TBL] [Abstract][Full Text] [Related]
12. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
13. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
Fujiwara T; Grimm EA; Mukhopadhyay T; Zhang WW; Owen-Schaub LB; Roth JA
Cancer Res; 1994 May; 54(9):2287-91. PubMed ID: 8162565
[TBL] [Abstract][Full Text] [Related]
14. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice.
Lesoon-Wood LA; Kim WH; Kleinman HK; Weintraub BD; Mixson AJ
Hum Gene Ther; 1995 Apr; 6(4):395-405. PubMed ID: 7612697
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
Wang WD; Li R; Chen ZT; Li DZ; Duan YZ; Cao ZH
Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
[TBL] [Abstract][Full Text] [Related]
16. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome.
Nakase M; Inui M; Okumura K; Kamei T; Nakamura S; Tagawa T
Mol Cancer Ther; 2005 Apr; 4(4):625-31. PubMed ID: 15827336
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
[TBL] [Abstract][Full Text] [Related]
18. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.
Densmore CL; Kleinerman ES; Gautam A; Jia SF; Xu B; Worth LL; Waldrep JC; Fung YK; T'Ang A; Knight V
Cancer Gene Ther; 2001 Sep; 8(9):619-27. PubMed ID: 11593330
[TBL] [Abstract][Full Text] [Related]
19. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy.
Moffatt S; Wiehle S; Cristiano RJ
Gene Ther; 2006 Nov; 13(21):1512-23. PubMed ID: 16763664
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector.
Ramesh R; Saeki T; Templeton NS; Ji L; Stephens LC; Ito I; Wilson DR; Wu Z; Branch CD; Minna JD; Roth JA
Mol Ther; 2001 Mar; 3(3):337-50. PubMed ID: 11273776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
